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A number of proteobacteria carry the genetic information
to perform N-linked glycosylation, but only the protein
glycosylation (pgl) pathway of Campylobacter jejuni has
been studied to date. Here, we report that the pgl gene
cluster of Campylobacter lari encodes for a functional gly-
cosylation machinery that can be reconstituted in
Escherichia coli. We determined that the N-glycan pro-
duced in this system consisted of a linear hexasaccharide.
We found that the oligosaccharyltransferase (OST) of
C. lari conserved a predominant speciﬁcity for the
primary sequence D/E–X−1–N–X+1–S/T (where X−1 and
X+1 can be any amino acid but proline). At the same time,
we observed that this enzyme exhibited a relaxed speci-
ﬁcity toward the acceptor site and modiﬁed asparagine
residues of a protein at sequences DANSG and NNNST.
Moreover, C. lari pgl glycosylated a native E. coli protein.
Bacterial N-glycosylation appears as a useful tool to estab-
lish a molecular description of how single-subunit OSTs
perform selection of glycosyl acceptor sites.
Keywords: Campylobacter lari, N-glycosylation,
oligosaccharyltransferase
Introduction
N-linked glycosylation is a ubiquitous protein modiﬁcation
that involves the decoration of selected asparagine residues
within the sequences N–X+1–S/T (X+1≠P) with an oligosac-
charide. This process is organized in a topologically equival-
ent way in eukaryotes and prokaryotes (Yurist-Doutsch et al.
2008) and involves (I) the assembly of the glycan donor on a
lipid anchor at the cytoplasmic side of the ER or of the
plasma membrane, (II) reorientation to the opposite face of
the membrane and (III) subsequent attachment to the acceptor
protein (Burda and Aebi 1999). The deﬁning event of
N-glycosylation is the formation of the N-glycosidic bond
between the oligosaccharide and the asparagine side chain of
the acceptor protein. This reaction is catalyzed by the oligo-
saccharyltransferase (OST), a single-subunit enzyme in bac-
teria, archea and protozoa, but a multimeric protein complex
in other eukaryotes (Kelleher and Gilmore 2006). The Stt3
protein represents the central component of the OST complex,
and it is believed to be the catalytic subunit (Feldman et al.
2005; Igura et al. 2008). However, limited structure/function
information on the Stt3 protein limits our understanding of
how the poorly reactive amido group of the asparagine side
chain is activated to form the N-glycosidic bond to the oligo-
saccharide (Igura et al. 2008; Maita et al. 2009).
An OST identiﬁes acceptor sequences in polypeptides and
modiﬁes only some of the potential sites. Amino acids around
the consensus sequence impact the probability of glycosyla-
tion of the particular site (Petrescu et al. 2004). According to
the current model, different strategies evolved to extend the
substrate range of N-linked glycosylation. Campylobacter
jejuni OST (called PglB) transfers a heptasaccharide to the
acceptor protein, stringently within the sequon D/E–X−1–N–
X+1–S/T (X−1, X+1 ≠P) (Kowarik, Young et al. 2006). In proto-
zoa, substrate diversity was extended through duplication of
the STT3 loci with subsequent diversiﬁcation of OST speci-
ﬁcity. In fact, Leishmania major and Trypanosoma brucei
bear different OST isoforms with distinct donor and acceptor
speciﬁcities (Nasab et al. 2008; Izquierdo et al. 2009). That is,
protozoa are able to assemble different glycans on distinct
sequons, thus increasing the complexity of their glycopro-
teome. In other eukaryotes, the core Stt3 is supplemented
with a variable number of additional functions that assist and
reﬁne the glycosylation process (Kelleher and Gilmore 2006).
Along this line, ribophorin I and Ost3/6p are connected to the
glycosylation status of membrane proteins and the site occu-
pancy of speciﬁc sequons, respectively (Wilson and High
2007; Schulz et al. 2009). These auxiliary OST subunits are
believed to preserve distinct protein substrates in an accessi-
ble, unfolded state, leading to an increased number of sites
accessible to the Stt3 protein.
Here, we attempted to mine the diversity of natural bacterial
OSTs in order to extend our understanding of bacterial
N-glycosylation. In particular, we investigated the role of the
acidic amino acid invariantly present in the consensus
sequence of C. jejuni glycoproteins and analyzed whether this
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requirement was conserved by N-glycosylation machineries of
other bacterial species. We found that the protein glycosyla-
tion (pgl) locus of Campylobacter lari encodes for a func-
tional glycosylation system, able to synthesize a linear
hexasaccharide and to transfer it to proteins. We observed that
ClPglB modiﬁed variants of the C. jejuni glycoprotein AcrA
that lack the canonical consensus sequence D/E–X−1–N–X+1–
S/T. We proved that ClPglB transfers the glycan to sites that
lack an acidic residue at the −2 position of the AcrA protein,
albeit with low efﬁciency. These data suggested that the nega-
tively charged amino acid of the glycosylation site was not
absolutely required for catalysis by bacterial OST, and it
raised the question whether the amino acid at the −2 position
was involved in the recognition of the acceptor site.
Furthermore, we observed that the nonconsensus sequence
DANSGT was glycosylated by ClPglB.
Results
C. lari pgl glycosylates proteins with a linear
hexasaccharide
The C. jejuni pgl cluster is the ﬁrst and the only bacterial glyco-
sylation system characterized to date. However, in the last few
years, genome sequencing unveiled a broad distribution of pgl
loci among ε- and δ-proteobacteria (Szymanski and Wren
2005). Some of the pgl loci share a genetic organization analo-
gous to the one of C. jejuni, whereas others present insertions
of a variable number of open reading frames (ORFs) between
the pgl genes. Interestingly, Helicobacter canadensis and
Helicobacter pullorum carry two pglB paralogs in distinct
locations of the chromosome (Langdon et al. 2009; Jervis et al.
2010). While pglB homologs exhibit a variable degree of simi-
larity in their sequences and there is not yet conclusive evidence
that they encode for functional OSTs, they all display the con-
served motif WWDXG and are predicted to arrange in a com-
parable topology. Moreover, analysis of the pgl loci revealed
the presence of functions involved in the bacillosamine biosyn-
thesis, suggesting that this monosaccharide might constitute a
common trait of Campylobacter N-glycosylation.
We studied the C. lari glycosylation system since we ident-
iﬁed signiﬁcant elements of difference among an overall
similarity to the C. jejuni pathway. The pgl cluster extends for
about 12 kb on the C. lari chromosome and contains 10
ORFs (Figure 1A). The gene (pglI) encoding for the glucosyl-
transferase that attaches the branching glucose to the C. jejuni
glycan was not found, whereas the other functions of the
C. jejuni pgl locus were identiﬁed based on sequence simi-
larity of the ORFs. ClPglB presents the WWDXG motif and
shares 56% identity to CjPglB. We isolated the C. lari pgl
locus and expressed it in combination with the C. jejuni AcrA
protein in Escherichia coli cells. Immunoblot analysis indi-
cated glycosylation of AcrA (Figure 1B). Puriﬁed glyco-
proteins were detected using serum speciﬁc for the C. jejuni
N-glycan (hR6) (Figure 1C). We have previously showed that
this serum recognizes a linear stretch of GalNAc residues
(Schwarz et al. 2010). Treatment of glycosylated AcrA with
an exo-α-N-acetyl-galactosaminidase (α-GalNAc-ase) resulted
in a mobility shift after sodium dodecyl sulfate (SDS)–poly-
acrylamide gel electrophoresis (PAGE) and in the gradual
reduction of reactivity to hR6 over time. This suggested that
the C. lari glycan contained a linear chain of GalNAc resi-
dues, linked in α conformation. To determine the structure of
the N-glycan of C. lari, AcrA was puriﬁed from E. coli cells
carrying either the C. jejuni or the C. lari pgl cluster, incu-
bated with proteinase K, permethylated and subjected to the
mass spectrometric (MS) analysis (Figure 1D). Comparison of
the two spectra revealed a difference in mass of 204 Da,
matching with a permethylated hexose. The MS/MS spectrum
of the ion at m/z = 2008.97 determined fragmentation behavior
compatible with a linear Bac(HexNAc)5 (Figure 1E).
Altogether, these data proved that the C. lari N-glycan con-
sisted of GalNAc-α-GalNAc-α-GalNAc-α-GalNAc-α-GalNAc-
1,3-Bac.
C. jejuni and C. lari pgl exhibit different acceptor
speciﬁcities
We aimed to dissect the C. lari PglB speciﬁcity toward the
acceptor protein and attempted a direct comparison to its
C. jejuni counterpart. AcrA presents ﬁve N-X-S/T sequences
(Figure 2A); two of them exhibit an acidic amino acid at the
−2 position to the asparagine and are glycosylated by CjPglB
(Kowarik, Young et al. 2006). Expression of AcrA in E. coli
bearing the C. jejuni or the C. lari pgl cluster led to a compar-
able pattern, as judged by immunoblot, corresponding to
AcrA glycosylated at two sites (Figure 2B, lanes 5 and 6).
The synthesis of glycosylation-incompetent AcrA N2,4L in the
presence of the C. jejuni pgl resulted in an unmodiﬁed accep-
tor (Figure 2B, lane 3), but expression of AcrA N2,4L in com-
bination with the C. lari pgl gave a pattern indicative of
glycosylation (Figure 2B, lane 4). The slowest migrating
protein, barely visible in the anti-AcrA immunoblot, produced
a signal with hR6, implying double glycosylation. This
suggested that the activity of ClPglB did not strictly depend
on the 5-mer consensus sequence as deﬁned in C. jejuni,
but it exhibited a different or broader substrate speciﬁcity.
Moreover, the hR6 serum speciﬁcally reacted with an
Fig. 1. Characterization of the C. lari N-glycan. (A) Genetic organization of the pgl cluster of C. lari. ORFs are represented by arrows. The names of genes were
assigned by homology to the C. jejuni pgl locus. Colors indicate putative functions involved in the biosynthesis of activated monosaccharides (red),
glycosyltransferases (blue), ﬂippase (cyan) and OST (green). (B) Periplasmic extracts from E. coli bearing the C. jejuni pgl cluster (lane 1), the plasmid pACYC184
(lane 2) or the C. lari pgl cluster (lane 3) and co-expressing AcrAwere analyzed by SDS–PAGE and immunoblot and probed with anti-AcrA serum (top) or hR6
(bottom). (C) Exo-α-GalNAc-ase digestion of the C. lari N-glycan. Puriﬁed AcrA from E. coli cell bearing the C. lari pgl locus was incubated with the glycosidase.
Aliquots taken at different time points were analyzed by SDS–PAGE, followed by Coomassie staining (top) or immunoblot with hR6 (bottom). (D) Glycosylated
AcrAwas digested with proteinase K, permethylated and subjected to matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis. Top
panel: AcrA carrying the C. jejuni glycan; bottom panel: AcrA carrying the C. lari glycan. The two main peaks display a difference in mass of 204 Da, matching
with a permethylated hexose. Minor peaks correspond to under-methylated glycans. (E) MALDI-MS/MS spectrum of the precursor ion at m/z = 2009, from AcrA
carrying the C. lari glycan. The fragment ions originating from the sequential loss of monosaccharide residues are indicated in the spectrum.
Acceptor site speciﬁcity of the Campylobacter lari PglB
47
additional periplasmic protein of E. coli cells bearing the C.
lari pgl cluster (Figure 2B, indicated with a star). In order to
identify this protein, we separated glycosylated proteins from
periplasmic extracts by soy bean agglutinin (SBA) lectin afﬁ-
nity chromatography (Supplementary data, Figure S1A) and
analyzed the resulting specimens by MS. We identiﬁed the
spermidine–putrescine-binding protein PotD of E. coli, pre-
viously reported not to be a substrate of the C. jejuni pgl
machinery (Kowarik, Young et al. 2006). Immunoblot analysis
conﬁrmed that endogenous PotD was modiﬁed by the C. lari
machinery (Figure 2C). Lastly, we conﬁrmed that the PotD
protein was modiﬁed at the sites DDN26NT and ESN62ET by
expression of histidine-tagged PotD variants presenting point
mutations in these sites (Supplementary data, Figure S1B).
Altogether, these data suggested that C. lari and C. jejuni pgl
possess different yet overlapping acceptor speciﬁcities.
C. lari PglB glycosylates AcrA lacking the
D/E–X−1–N–X+1–S/T site
To investigate whether bacterial OSTs generally exhibit sub-
strate speciﬁcities different from that of C. jejuni, we designed
two versions of the AcrA acceptor protein. In the C. jejuni
system, the AcrA N273Q mutant conserves a single glycosyla-
tion site, while the double mutation D121A/N273Q prevents
glycosylation. We analyzed the glycosylation proﬁle of these
AcrAvariants in E. coli SCM3 bearing a plasmid to direct syn-
thesis of the C. jejuni glycan and a plasmid encoding for the
PglB from C. jejuni, Campylobacter coli or C. lari (Figure 3).
Fig. 2. C. jejuni and C. lari pgl present different acceptor speciﬁcities. (A) Schematic representation of the ﬁve glycosylation sites of AcrA. (B) Periplasmic
extracts from E. coli bearing the C. jejuni or the C. lari pgl cluster and expressing either wild-type AcrA or the variant N123L/N273L (N2,4L) were analyzed by
SDS–PAGE and immunoblot and probed with anti-AcrA serum (top panel) or anti-glycan hR6 (lower panel). Star indicates the C. lari pgl-speciﬁc protein which
reacts to the hR6 serum. Numbers on the left of the gel frame show the electrophoretic mobility of the molecular weight marker. The numbers of N-glycans on
AcrA are indicated at the right side of the gel frame. (C) Periplasmic extracts from E. coli bearing the C. lari pgl cluster in combination with the pBR322 vector
(lanes 1 and 2) or a plasmid encoding for AcrA (lanes 3 and 4) were analyzed by immunoblot and probed with anti-glycan (top), anti-PotD (middle) or
anti-AcrA serum (bottom). Glycosylated proteins were incubated with (lanes 2 and 4) or without (lanes 1 and 3) α-GalNAc-ase.
F Schwarz et al.
48
Both C. coli and C. lari PglB transferred the C. jejuni glycan
to AcrA N273Q, albeit with very low efﬁciency in the case of
C. coli (Figure 3, lanes 5 and 7). Strikingly, we could observe
glycosylation of the AcrA D121A/N273Q variant only by C.
lari PglB (Figure 3, lane 8). We speculated that the detected
glycosylated product could be either due to glycosylation at a
distinct site or due to a mixed population of AcrA glycoforms,
each weakly glycosylated at a different site.
Therefore, we undertook a comprehensive analysis of AcrA
glycosylation by the C. lari system. We ﬁrst generated mutant
forms of AcrA containing N-to-L replacements at each of
the N–X–S/T sites and studied their glycosylation proﬁle
(Figure 4A). Disruption of the sites at N117 (N1L), N145
(N3L) and N274 (N5L) gave a phenotype similar to the wild-
type AcrA (Figure 4A, lanes 3, 5 and 7). The N123L (N2L)
mutation clearly affected glycosylation, implying that the site
N123 was used by ClPglB (Figure 4A, lane 4). Interestingly,
mutation of the N273 (N4L) reduced the ratio between doubly
and mono-glycosylated AcrA (Figure 4A, lane 6). This
suggested that the inactivation of the N4 site led to inefﬁcient
modiﬁcation of an alternative site. At this point, we specu-
lated that the mutation of N4 directed glycosylation of the
adjacent site N5.
We further constructed a series of AcrA variants presenting
multiple point mutations. These proteins were expressed in E.
coli carrying the C. lari pgl locus, puriﬁed via nickel afﬁnity
chromatography and analyzed by SDS–PAGE. To convin-
cingly demonstrate glycosylation, we incubated the AcrA
preparations with α-GalNAc-ase. Puriﬁed fractions from cells
expressing the triple mutants N117L/N123L/N273L (N1,2,4L)
and N123L/N145L/N273L (N2,3,4L) AcrAs were resolved as a
major protein with a mass of about 37 kDa and two larger
proteins as visualized by Coomassie staining (Figure 4B,
lanes 1 and 3). These proteins were sensitive to glycosidase
treatment, suggesting glycosylation (lanes 2 and 4). The hR6
immunoblot supported this observation. Concomitant
mutation of the N123, N273 and N274 sites (N2,4,5L) resulted
in a single hR6-reactive protein (Figure 4B, lane 5). hR6 reac-
tivity disappeared after glycosidase treatment (lane 6). This
led us to conclude that N5 was glycosylated by ClPglB.
Surprisingly, simultaneous mutation of four (N1,2,4,5L) or all
ﬁve (N1,2,3,4,5L) asparagine residues within the N–X–S/T sites
gave a phenotype equivalent to the triple mutant N2,4,5L
(Figure 4B, lanes 7–10). After careful inspection of the AcrA
sequence, we suspected that the site 257DANSGT262 might
represent an alternative, suboptimal glycosylation site. Indeed,
inactivation of this site by mutation of the asparagine residue
(N6) prevented glycosylation by ClPglB (Figure 4B, lane 11).
In order to conclusively prove that the N5 and N6 sites
were glycosylated, we performed the MS analysis. To over-
come the issue of limiting ionization efﬁciency of glycopep-
tides, we took advantage of the newly generated data on the
C. lari N-glycan and developed a procedure to produce useful
N-glycopeptides. We incubated nickel afﬁnity-puriﬁed AcrA
variants with trypsin and then, after heat inactivation of the
protease, added α-GalNAc-ase. In this way, we produced a
mixture of peptides and corresponding bacillosamine-tagged
glycopeptides that were subjected to the liquid chromatography-
electrospray ionization mass spectrometry (LC-ESI-MS) analy-
sis. The fragmentation spectrum of the triply charged precursor
ion at m/z = 923.8 matched with the unmodiﬁed peptide
AVFDNQN5STLLPGAFATITSEGFIQK (Supplementary data,
Figure S2A), whereas the fragmentation proﬁle of the triply
charged precursor ion at m/z = 999.8 was consistent with the
presence of bacillosamine at N5 of the same peptide
(Figure 4C). Similarly, the MS/MS proﬁle of the doubly
charged precursor ion at m/z = 871.5 matched with the peptide
LYFIDSVIDAN6SGTVK (Supplementary data, Figure S2B),
and ions generated by the fragmentation of the species at m/z =
985.5 (doubly charged) were in agreement with bacillosamine-
tagged N6 of the same peptide (Figure 4D). Consequently,
glycosylation at the sites DNQNST, DNLNST and DANSGT
illustrated that precise positioning of the D/E and S/T residues
was not essential on speciﬁc sites of AcrA.
A D/E residue at −2 position is not absolutely required
for ClPglB glycosylation
Next, we examined the glycosylation proﬁle of AcrA N2L
presenting a D-to-A substitution in the 271DNN
4N5ST276 site
(Figure 5A). Remarkably, ClPglB transferred a glycan to the
ANN4N5ST site, implying that aspartic acid was not essential
for catalysis (lanes 1 and 2 and 7 and 8). MS/MS analysis of
the precursor ion at the mass corresponding to the glycosy-
lated peptide (m/z = 2940) did not allow us to clearly assign
the glycan at N4 or N5 (Supplementary data, Figure S3).
We extended the study to glycosylation of the DNN4N5AT
and DNN4N5SA sites. We observed a gradual increase in the
glycosylation efﬁciency, with ANN4N5ST site being modiﬁed
the least (Figure 5A, lane 1) and DNN4N5SA the most
(Figure 5A, lane 5). This indicated that the aspartic acid had
an active role in recruiting the substrate to PglB. Although we
did not determine the position of the glycan in the
DNN4N5AT site, we reasoned that this was a similar situation
to DNQN5ST and DNLN5ST. Accordingly, the S275A
mutation provided a suboptimal substrate, whereas T276A
resulted in an optimal acceptor site sequence for ClPglB.
ClPglB does not glycosylate a eukaryotic protein
at the native glycosylation site
We ruled out the hypothesis that the acidic amino acid in the
−2 position was strictly required for catalysis by ClPglB. In
Fig. 3. AcrA glycosylation by bacterial OSTs. Periplasmic extracts of E. coli
cells transformed with the mutated C. jejuni pgl cluster (pglMut), expressing
either AcrA N273Q (lanes 1, 3, 5 and 7) or AcrA D121A/N273Q (lanes 2, 4,
6 and 8), and bearing a plasmid encoding for C. jejuni (lanes 3 and 4),
C. coli (lanes 5 and 6) or C. lari (lanes 7 and 8). Proteins were separated by
SDS–PAGE and probed with anti-AcrA serum. The numbers of N-glycans on
AcrA are indicated at the right side of the gel frame.
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Fig. 4. ClPglB glycosylates AcrA at two noncanonical sites. (A) Periplasmic extracts from E. coli expressing single-site AcrAvariants were analyzed by SDS–
PAGE and immunoblot and probed with anti-AcrA serum (top) or hR6 (bottom). Numbers at the right of the gel frame indicate the N-glycans on AcrA. (B)
Nickel afﬁnity-puriﬁed AcrAvariants were separated by SDS–PAGE, stained by Coomassie (top) or transferred to nitrocellulose membranes and probed with hR6
serum (bottom). AcrAs were incubated with (+) or without (−) α-GalNAc-ase. (C) LC-ESI-MS/MS analysis of AcrA D121A/N273Q, puriﬁed from E. coli cells
bearing the C. lari pgl cluster. Spectrum from fragmentation of the triply charged precursor ion at m/z = 999.8 corresponds to the glycopeptide AVFDNQN(Bac)
STLLPGAFATITSEGFIQK. (D) LC-ESI-MS/MS analysis of AcrA N123L D271A. Spectrum from fragmentation of the doubly charged ion at m/z = 985.5
matches with the glycopeptides LYFIDSVIDAN(Bac)SGTVK.
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order to test whether ClPglB was active toward the short,
eukaryotic glycosylation site N–X–S/T, we examined the gly-
cosylation of a eukaryotic protein. We chose immunoglobulin
G (IgG) as model acceptor protein because detailed structural
information is available for this molecule. IgGs are invariably
decorated with a glycan within the QYNST sequon of the
CH2 domain. Analyses of glycosylated and un-glycosylated
IgG fragments have revealed that the glycosylation site is
located in an extended loop connecting two β-strands
(Prabakaran et al. 2008; Girardi et al. 2009). This implies that
the acceptor site folds in a ﬂexible structure, a possible prere-
quisite for CjPglB (Kowarik, Numao et al. 2006). However,
expression of wild-type CH2 domain of a human IgG1 in
E. coli bearing the pgl machinery did not result in glycosyla-
tion of the CH2 protein (Figure 6A). In contrast, the protein
variant Q92E was recognized as a substrate and glycosylated.
Discussion
During N-linked glycosylation, only a subset of potential
acceptor sites is chosen for glycosylation. In yeast and higher
eukaryotes, site selection is aided by the concerted activity of
the OST subunits, which present speciﬁc polypeptides to the
Stt3 protein. A similar advantage has been achieved in some
protozoa by duplication of the STT3 gene: OST isoforms fea-
turing various degrees of similarity direct glycosylation of dis-
tinct subsets of polypeptides. A limited number of
proteobacteria possess a protein N-glycosylation system, prob-
ably acquired by the horizontal transfer from archaea.
Although duplication of the gene encoding for the OST has
been observed in rare cases, most bacteria carry a single copy
of pglB on the genome. In this respect, N-glycosylating bac-
teria are likely to mimic an early evolutionary stage. Therefore,
bacterial systems appear as ideal candidates to establish an
accurate molecular description of how a single-subunit OST
performs site selection. This will in turn shed light on the cata-
lytic mechanism of N-glycosylation. Lastly, access to bacterial
glycosylation systems represents an important means to
explore and exploit the diversity of this glycosylation.
CjPglB modiﬁes asparagine residues within the sequence D/
E–X−1–N–X+1–S/T (where X−1 and X+1 are any amino acids
but proline) when located in ﬂexible, exposed structural
elements (Kowarik, Numao et al. 2006; Kowarik, Young et al.
2006). The presence of an acidic group at the −2 position to
the asparagine seems to be a common prerequisite of CjPglB
and ClPglB for efﬁcient glycosylation. However, weak glyco-
sylation of AcrA at the NNNST site by ClPglB illustrates that
the acidic amino acid is dispensable for catalysis in vivo and
corroborates the hypothesis that the formation of the
N-glycosidic bond proceeds via a reaction scheme conserved
in bacteria and eukaryotes. Similar conclusions have been
drawn from the observation that tripeptides of sequence NLT
are modiﬁed in vitro by membrane fractions containing
CjPglB, in the presence of synthetic lipid-linked oligosacchar-
ides (Glover et al. 2005). Both in vivo and in vitro, the pres-
ence of the aspartic acid at the −2 position greatly enhances the
efﬁciency of the reaction. Although it is tempting to invoke
involvement of the negatively charged amino acid in the recruit-
ment of acceptor substrate to PglB, the exact role of the −2 pos-
ition remains elusive. In fact, peptides with the semi-consensus
sequence DFNVX (X = cysteine, homoserine or diaminopropio-
nic acid) are neither substrates of CjPglB nor behave as inhibi-
tors in vitro (Chen et al. 2007). Similarly, DFQRT peptides do
not seem to reduce glycosylation of AcrA in vitro (data not
shown). This evidence supports a more complex role for the −2
position. It might be that the aspartic acid, which is a poor
α-helix former (Pace and Scholtz 1998), enhances the ﬂexibility
required by PglB. Thus, the D121A mutation on AcrA might
preclude glycosylation at N2 by a double effect—reduction of
ﬂexibility plus a drop in recognition by PglB. In contrast, the
N4/N5 sites are predicted to fold in a ﬂexible conformation
(Kowarik, Young et al. 2006), and their local structure might be
unaffected by the mutation of D271. However, while this
hypothesis supports site occupancy of AcrA, it does not explain
why IgG1-CH2 is not glycosylated.
Although we cannot formally exclude the possibility that
heterologous expression of pgl genes in E. coli might affect
Fig. 5. Acidic amino acid is dispensable for AcrA glycosylation at a distinct
site. Nickel afﬁnity-puriﬁed AcrA variants were separated by SDS–PAGE,
stained by Coomassie (top) or transferred to nitrocellulose membranes and
probed with hR6 (bottom) sera. AcrAvariants were incubated with (+) or
without (−) α-GalNAc-ase.
Fig. 6. ClPglB does not glycosylate a eukaryotic protein at the native
glycosylation site. SDS–PAGE and immunoblot analysis of periplasmic
extracts from E. coli cells expressing histidine-tagged CH2 protein variants.
Membranes were probed with anti-histidine tag antibodies (top) or hR6 serum
(bottom).
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their speciﬁcities or that Pgl protein levels might differ, selec-
tive modiﬁcation of the PotD protein by ClPglB demonstrates
that bacterial glycosylation machineries feature different glyco-
sylation phenotypes. However, the evidence that native E. coli
proteins are rarely glycosylated suggests that Campylobacter
acceptor proteins co-evolved with pgl systems and are thus
tuned to accept N-glycans.
Glycosylation of the sequence DANSG is unusual. The
vast majority of all N-glycans is found within the sequence
N-X+1–S/T (where X+1 can be any amino acid but proline)
(Marshall 1974). Atypical N-glycosylation sites bearing the
NXC sequence have been reported for eukaryotic proteins
including CD69 (Vance et al. 1997), immunoglobulin µ chain
(Kehry et al. 1979), human leptin receptor (Haniu et al. 1998)
and von Willebrand factor (Titani et al. 1986). Additionally, a
recent global LC-MS/MS analysis of murine glycopeptides
has extended the spectrum of nonconsensus recognition
motifs to include N–G–X and N–X–V sequences (Zielinska
et al. 2010). Structural studies have indicated that the amide
of the asparagine networks to the hydroxyl group of the +2
position to form an Asn turn (Imperiali and Hendrickson
1995) and that the side chain of the amino acid at the +1 pos-
ition are displaced out of this conformation. However, glyco-
sylation of nonconsensus sequences shows that the Asn-turn
motif might not be strictly required for protein modiﬁcation.
Recently, it has been described that the asparagine of the non-
canonical NSG sequence of the CH1 domain of human IgG1
is partially glycosylated (Valliere-Douglass et al. 2009). This
ﬁnding seems similar to what we report on the NSG site of
AcrA. Both observations demonstrate that bacterial and
eukaryotic OSTs share a similar basis for the recognition of
glycosyl acceptor sites. Moreover, occurrence of this particu-
lar glycosylation both in bacteria and in eukaryotes implies
that this activity is intrinsic in the PglB/Stt3 protein, and it is
not due to the absence of potential acceptor substrates. In a
follow-up paper, Valliere-Douglass et al. (2010) identiﬁed
additional noncanonical glycosylation sites in IgG1 and pro-
posed that the common feature of these unusual low-
efﬁciency glycosylation sites is the presence of a “reverse-
consensus” motif (serine/threonine residue at the −2 position
relative to the modiﬁed asparagine residue). Therefore, the
DANSG site of AcrA might not belong to this class of atypi-
cal glycosylation sequences.
Further investigation will be needed to unravel the biologi-
cal signiﬁcance of this relaxed glycosylation, whether this has
to be regarded as a limitation in the ﬁdelity of OST or as a
strategy to extend the number of N-glycosylations.
Materials and methods
Construction of plasmids
All the strains and plasmids used in this study are listed in
Supplementary data, Table SI. Oligonucleotides were pur-
chased from Microsynth (Balgach, Switzerland). Unless other-
wise stated, E. coli DH5α was chosen as host for cloning.
Restriction enzymes were purchased from NEB or Fermentas.
T4 DNA ligase was from NEB. Plasmid pFLA29 was con-
structed by annealing of oligos 5′-TGTAGTTAATTAACGA
TGATAAAAATCTAGCGCTGAGGCAGTGCTGAGC-3′ and
5′-GCTCAGCACTGCCTCAGCGCTAGATTTTTATCATCGTT
AATTAAC-3′ and subsequent ligation into pACYC184, pre-
viously cut with BfmI and Bpu1102I. Cloning of the C. lari
pgl cluster was performed by three overlapping polymerase
chain reaction (PCR) fragments and homologous recombination
in yeast (Oldenburg et al. 1997). Integration of the PCR frag-
ments into the SmaI-linearized YEp352 vector was achieved by
homologous recombination in SS328 yeast strain during trans-
formation. Transformants were selected on synthetic minimal
medium lacking uracil, and recombined plasmids were isolated
from yeast cells (Sherman 2002). After re-transformation in
E. coli, plasmids were conﬁrmed by restriction digestion. A 12
kb fragment was released from YEp352(pgl4) by digestion
with PacI and Bpu1102I and ligated into the corresponding
sites of pFLA29, thus producing pACYC(pgl4). Plasmid
pFLA26 was constructed by subcloning the PsiI/SpeIAcrA
fragment from pMIK43 into pFLA19. The pglB ORFs were
ampliﬁed by PCR using C. coli gDNA and C. lari gDNA.
Fragments containing CcpglB were cut with XbaI/HindIII and
ligated into pMLBAD, previously cut with the same enzymes.
Fragments containing ClpglB were cut with EcoRI and PstI
and ligated into pMLBAD, previously cut with the same
enzymes. All pglB ORFs are in frame with an HA tag at the
C-terminus. The potD gene of E. coli MC1067 was ampliﬁed
and cloned into pEC415 previously cut with NdeI and EcoRI.
All point mutations were inserted by site-directed mutagenesis
with the QuickChange Kit from Stratagene. All constructs were
conﬁrmed by restriction analysis and sequencing of relevant
fragments (Synergene AG, Switzerland).
Protein expression, puriﬁcation and analysis
E. coli SCM3 or SCM6 harboring pACYC(pgl) or pACYC
(pgl4) and a plasmid coding for an acceptor protein were
grown overnight from single colonies at 37°C in volumes of
10 mL of Luria-Bertani (LB) medium. Ampicillin (100 mg/
L), trimethoprim (100 mg/L) and chloramphenicol (25 mg/L)
were added to the medium, as needed. Preparation of periplas-
mic extracts was carried out by lysozyme treatment, consisting
of an incubation in 30 mM Tris–HCl pH 8.5, 20% (w/v)
sucrose, 1 mM EDTA, 1 mg/mL lysozyme (Sigma), for 1 h on
ice. Spheroblasts were removed by centrifugation. For protein
puriﬁcation, cultures were scaled up to 0.5 L. For AcrA puriﬁ-
cation, periplasmic extracts were supplemented with imidazole
to reach a ﬁnal concentration of 10 mM, sterile-ﬁltered (0.22
µm) and puriﬁed by nickel afﬁnity chromatography using
Ni-NTA agarose (Qiagen). For the separation of glycosylated
proteins, periplasmic extracts were dialyzed twice against
phosphate-buffered saline (PBS) pH 7.4 and loaded onto an
SBA-agarose (Vector laboratories Inc., CA) column. After
washing with PBS, bound proteins were eluted with PBS con-
taining 0.5 M galactose. SDS–PAGE was performed accord-
ing to Lämmli; immunodetection was performed with
polyclonal anti-AcrA serum (Wacker et al. 2002), polyclonal
hR6 serum (S. Amber and M. Aebi, in preparation), polyclo-
nal anti-PotD serum (Furuchi et al. 1991) and monoclonal
anti-His antibody (Qiagen). For the removal of the GalNAc
residues from N-glycan, 3 µg of glycoproteins was
incubated for 3 h (unless differently speciﬁed) with 40 U
of exo-α-N-acetyl-galacosaminidase (NEB) in the presence of
4 µg of bovine serum albumin in 50 mM Tris buffer pH 7.5.
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MS analysis
For the characterization of the N-glycan of C. lari, 50 µg of gly-
coproteins was incubated with proteinase K (Sigma), overnight
at 37°C, at a 1:50 (w/w) enzyme: substrate ratio. Digestion pro-
ducts were passed through a carbon column (ENVI-Carb SPE,
Supelco), washed with 0.1% formic acid (FA) and eluted with
25% acetonitrile (ACN), 0.1% FA. Eluent was permethylated
and spotted on the plate with 2,5-dihydroxybenzoic acid (DHB)
matrix (10 mg/mL in 50% ACN and 0.1% FA). MALDI-MS
and MS/MS were acquired in the positive ion reﬂectron mode
by MALDI-TOF/TOFMS with 4800 MALDI TOF/TOF
Analyzer instrument (Applied Biosystems, CA). For glycopep-
tide identiﬁcation, 0.1 mg of glycoproteins was incubated with
trypsin (Promega), overnight at 37°C. After heat inactivation,
tryptic digestion products were further treated with
exo-α-N-acetyl-galacosaminidase from 8 h to overnight.
Sep-Pak C18 was used to desalt and remove enzymes. Peptides
were eluted with 70% ACN and 0.1% FA and analyzed with an
LTQ-FT-ICR-MS instrument (Thermo Scientiﬁc, MA).
Samples were injected into an Eksigent-nano-HPLC system
(Eksigent Technologies, CA) by an autosampler and separated
on a self-made reverse-phase tip column (75 µm × 80 mm)
packed with C18 material (AQ, 3 µm, 200 A, Bischoff GmbH,
Germany). The column was equilibrated with solvent A (A: 3%
ACN and 0.2% FA, in water). Peptides were eluted using the
following gradient: 0–50 min, 0–60% B; 50–53 min, 60–97%
B; 53–60 min, 97% B (B: 80% ACN and 0.2% FA, in water) at
a ﬂow rate of 0.2 µL/min. High accuracy mass spectra were
acquired at an LTQ-ICR-FT in the mass range of 300–2000 m/z
and a target value of 5 × 105 ions. Up to four data-dependent
MS/MS spectra of the most intense ions with charge state 2+ or
higher were recorded in parallel at the ion trap using
collision-induced dissociation.
Supplementary data
Supplementary data for this article is available online at
http://glycob.oxfordjournals.org/.
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